Previous close | 0.7100 |
Open | 0.7100 |
Bid | 0.6850 x N/A |
Ask | 0.7500 x N/A |
Day's range | 0.6700 - 0.7150 |
52-week range | 0.4100 - 1.3500 |
Volume | |
Avg. volume | 97,654 |
Market cap | 210.111M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) System.
EBR Systems, Inc. (ASX: "EBR", "EBR Systems", or the "Company"), developer of the world's only wireless cardiac pacing system for heart failure, is pleased to announce that the Company's WiSE® technology will be featured at the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore from the 18th to the 20th of November.